rome and Keratosis--Actinic

Actinic keratosis (AK) is a photo-induced skin lesion. It has been considered by several authors as in-situ squamous cell carcinoma (SCC), that can evolve to invasive SCC (iSCC). Given the malignant potential and because it is impossible predict which AK will evolve in iSCC, it is necessary to treat each lesion. Multiple therapeutic approaches have been described to treat AKs. In addition to the topical drugs, photodynamic therapy (PDT) has become an established therapeutic modality for grade I and II of AKs of face and scalp. Recently the daylight photo-dynamic therapy (DL-PDT) has found extensive use in the care of the AK and in the field cancerization.. The study included 101 patients, 90 males and 11 females, mean age 71, phototype I-II, with multiple AK I and II of the face and the scalp, treated with DL-PDT. Patients were clinically evaluated for 3 months. The aim of this study was to show our experience in Daylight Photodynamic Therapy, to confirm the validity in term of efficacy and safety of DL-PDT for I and II AK of face and scalp and to underline the patient's higher satisfaction for this type of treatment and his availability to be retreated with the DL-PDT.. The efficacy was complete in 16 patients (15.8%), in 71 patients (70.3%) was much improved or improved and only in 14 (13.9%) subjects were minimal, while nobody had worsened or changed. The majority of patients (84.2%) patients were satisfied of the efficacy as well of the cosmetic results, only 15 (14.9%) were low satisfied and one patient was not satisfied.. This study confirms that the DL-PDT is a good alternative to c-PDT for the treatment of grade I and II AK of the face and scalp and in Rome, as in Southern Europe, it is possible to perform the DL-PDT in almost every month of year.

Topics: Aged; Aged, 80 and over; Cohort Studies; Face; Female; Humans; Keratosis, Actinic; Male; Middle Aged; Patient Satisfaction; Photochemotherapy; Retrospective Studies; Rome; Scalp; Sunlight; Treatment Outcome

Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Female; Gels; Humans; Hyaluronic Acid; Keratosis, Actinic; Male; Middle Aged; Patient Compliance; Photochemotherapy; Photosensitizing Agents; Quality of Life; Rome; Severity of Illness Index; Skin; Time Factors; Treatment Outcome